The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06479135




Registration number
Help: Registration number
NCT06479135
Ethics application status
Help: Ethics application status
Date submitted
Help: Date submitted
21/06/2024
Date registered
Help: Date registered
28/06/2024
Date last updated
Help: Date last updated
25/09/2025

Titles & IDs
Public title
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Scientific title
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Additional trial identifiers [1] 0 0
KRT-232-115
Universal Trial Number (UTN)
Trial acronym
POIESIS
Related trial records

Health condition
Health condition(s) studied:
Myelofibrosis 0 0
Post-PV MF 0 0
Post-ET Myelofibrosis 0 0
Primary Myelofibrosis 0 0
MF 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Treatment: Drugs - Navtemadlin
Treatment: Drugs - Navtemadlin placebo
Treatment: Drugs - Ruxolitinib

Experimental: Arm 1 - Navtemadlin administered orally once daily on Days 1-7, off treatment on Days 8-28, in 28-day treatment cycles. Ruxolitinib administered orally twice a day.

Active comparator: Arm 2 - Navtemadlin placebo administered orally once daily on Days 1-7, off treatment on Days 8-28, in 28-day treatment cycles. Ruxolitinib administered orally twice a day.


Treatment: Drugs: Navtemadlin
Navtemadlin is an investigational MDM2 inhibitor

Treatment: Drugs: Navtemadlin placebo
Navtemadlin placebo

Treatment: Drugs: Ruxolitinib
Ruxolitinib is a janus kinase 1/2 inhibitor

Intervention code [1] 0 0
Treatment: Drugs
Description of the comparator or control
Control group

Outcomes
Primary outcome [1] 0 0
To compare spleen volume reduction (SVR35) between Arm 1 and Arm 2
Timepoint [1] 0 0
24 weeks
Primary outcome [2] 0 0
To compare total symptom score reduction (TSS50) between Arm 1 and Arm 2
Timepoint [2] 0 0
24 weeks
Secondary outcome [1] 0 0
To compare time to progression between Arm 1 and Arm 2
Timepoint [1] 0 0
Up to 8 years
Secondary outcome [2] 0 0
To compare overall survival (OS) between Arm 1 and Arm 2
Timepoint [2] 0 0
Up to 8 years

Eligibility
Key inclusion criteria
Inclusion Criteria for Ruxolitinib Alone Period:

* Confirmed diagnosis of PMF, post-PV MF, or post-ET MF, as assessed by the treating physician according to the World Health Organization (WHO) criteria
* High, Intermediate-1, Intermediate-2 risk category International Prognosis System Score (IPSS)
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
* JAK-inhibitor treatment naive
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Exclusion Criteria for Ruxolitinib Alone Period:

* Prior Splenectomy
* Splenic irradiation within 3 months prior to the first dose
* Prior BCL-XL, BET, MDM2, PI3K, PIM, or XPO1 inhibitors therapy or p53-directed therapy
* Eligible for Bone Marrow Transplant
* Peripheral blood or bone marrow blast count = 10 percent

Inclusion Criteria for Randomized Period:

* PMF, post-PV MF, or post-ET MF that is TP53WT as assessed by central testing
* ECOG performance status of 0 to 2
* Treatment with a stable dose of ruxolitinib
* Suboptimal response to run-in ruxolitinib treatment

Exclusion Criteria for Randomized Period:

* Elevated white blood cell count that doubles (or more) during ruxolitinib treatment and exceeds 50 × 10^9/L
* Peripheral blood or bone marrow blast count = 10 percent

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
TAS,WA
Recruitment hospital [1] 0 0
Royal Hobart Hospital (RHH) - Hobart
Recruitment hospital [2] 0 0
Sir Charles Gairdner Hospital - Nedlands
Recruitment hospital [3] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [4] 0 0
Monash Medical Center Clayton - Clayton
Recruitment hospital [5] 0 0
Townsville University Hospital - Douglas
Recruitment hospital [6] 0 0
Gosford Hospital - Gosford
Recruitment hospital [7] 0 0
St George Hospital - Kogarah
Recruitment hospital [8] 0 0
The Royal Melbourne Hospital - Peter MacCallum Cancer Center - Melbourne
Recruitment hospital [9] 0 0
The Alfred Hospital - Melbourne
Recruitment hospital [10] 0 0
Royal Perth Hospital - Perth
Recruitment hospital [11] 0 0
Calvary Mater Newcastle Hospital - Waratah
Recruitment postcode(s) [1] 0 0
7000 - Hobart
Recruitment postcode(s) [2] 0 0
6009 - Nedlands
Recruitment postcode(s) [3] 0 0
SA 5000 - Adelaide
Recruitment postcode(s) [4] 0 0
VIC 3168 - Clayton
Recruitment postcode(s) [5] 0 0
QLD 4814 - Douglas
Recruitment postcode(s) [6] 0 0
NSW 2250 - Gosford
Recruitment postcode(s) [7] 0 0
NSW 2217 - Kogarah
Recruitment postcode(s) [8] 0 0
VIC 3000 - Melbourne
Recruitment postcode(s) [9] 0 0
VIC 3004 - Melbourne
Recruitment postcode(s) [10] 0 0
6000 - Perth
Recruitment postcode(s) [11] 0 0
NSW 2298 - Waratah
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Delaware
Country [6] 0 0
United States of America
State/province [6] 0 0
District of Columbia
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Iowa
Country [9] 0 0
United States of America
State/province [9] 0 0
Kansas
Country [10] 0 0
United States of America
State/province [10] 0 0
Kentucky
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Nebraska
Country [16] 0 0
United States of America
State/province [16] 0 0
Nevada
Country [17] 0 0
United States of America
State/province [17] 0 0
New Jersey
Country [18] 0 0
United States of America
State/province [18] 0 0
New York
Country [19] 0 0
United States of America
State/province [19] 0 0
North Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Ohio
Country [21] 0 0
United States of America
State/province [21] 0 0
Oregon
Country [22] 0 0
United States of America
State/province [22] 0 0
Pennsylvania
Country [23] 0 0
United States of America
State/province [23] 0 0
Tennessee
Country [24] 0 0
United States of America
State/province [24] 0 0
Texas
Country [25] 0 0
United States of America
State/province [25] 0 0
Utah
Country [26] 0 0
United States of America
State/province [26] 0 0
Virginia
Country [27] 0 0
United States of America
State/province [27] 0 0
Washington
Country [28] 0 0
United States of America
State/province [28] 0 0
Wisconsin
Country [29] 0 0
Austria
State/province [29] 0 0
Graz
Country [30] 0 0
Austria
State/province [30] 0 0
Innsbruck
Country [31] 0 0
Austria
State/province [31] 0 0
Leoben
Country [32] 0 0
Austria
State/province [32] 0 0
Linz
Country [33] 0 0
Austria
State/province [33] 0 0
Vienna
Country [34] 0 0
Belgium
State/province [34] 0 0
Antwerp
Country [35] 0 0
Belgium
State/province [35] 0 0
Leuven
Country [36] 0 0
Belgium
State/province [36] 0 0
Liège
Country [37] 0 0
Belgium
State/province [37] 0 0
Roeselare
Country [38] 0 0
Belgium
State/province [38] 0 0
Yvoir
Country [39] 0 0
Croatia
State/province [39] 0 0
Rijeka
Country [40] 0 0
Croatia
State/province [40] 0 0
Split
Country [41] 0 0
Croatia
State/province [41] 0 0
Šibenik
Country [42] 0 0
Croatia
State/province [42] 0 0
Zagreb
Country [43] 0 0
Czechia
State/province [43] 0 0
Brno
Country [44] 0 0
Czechia
State/province [44] 0 0
Hradec Králové
Country [45] 0 0
Czechia
State/province [45] 0 0
Ostrava
Country [46] 0 0
Czechia
State/province [46] 0 0
Prague
Country [47] 0 0
France
State/province [47] 0 0
Paris
Country [48] 0 0
France
State/province [48] 0 0
Amiens
Country [49] 0 0
France
State/province [49] 0 0
Angers
Country [50] 0 0
France
State/province [50] 0 0
Lille
Country [51] 0 0
France
State/province [51] 0 0
Lyon
Country [52] 0 0
France
State/province [52] 0 0
Nantes
Country [53] 0 0
France
State/province [53] 0 0
Nice
Country [54] 0 0
France
State/province [54] 0 0
Nîmes
Country [55] 0 0
France
State/province [55] 0 0
Pessac
Country [56] 0 0
France
State/province [56] 0 0
Poitiers
Country [57] 0 0
France
State/province [57] 0 0
Strasbourg
Country [58] 0 0
France
State/province [58] 0 0
Toulouse
Country [59] 0 0
France
State/province [59] 0 0
Tours
Country [60] 0 0
Georgia
State/province [60] 0 0
Kutaisi
Country [61] 0 0
Georgia
State/province [61] 0 0
Tbilisi
Country [62] 0 0
Germany
State/province [62] 0 0
Düsseldorf
Country [63] 0 0
Germany
State/province [63] 0 0
Freiburg im Breisgau
Country [64] 0 0
Germany
State/province [64] 0 0
Halle
Country [65] 0 0
Germany
State/province [65] 0 0
Hamburg
Country [66] 0 0
Germany
State/province [66] 0 0
Hanover
Country [67] 0 0
Germany
State/province [67] 0 0
Heidelberg
Country [68] 0 0
Germany
State/province [68] 0 0
Jena
Country [69] 0 0
Germany
State/province [69] 0 0
Kiel
Country [70] 0 0
Germany
State/province [70] 0 0
Leipzig
Country [71] 0 0
Germany
State/province [71] 0 0
Munich
Country [72] 0 0
Germany
State/province [72] 0 0
Mutlangen
Country [73] 0 0
Germany
State/province [73] 0 0
Nuremberg
Country [74] 0 0
Germany
State/province [74] 0 0
Stuttgart
Country [75] 0 0
Germany
State/province [75] 0 0
Ulm
Country [76] 0 0
Greece
State/province [76] 0 0
Athens
Country [77] 0 0
Greece
State/province [77] 0 0
Ioannina
Country [78] 0 0
Greece
State/province [78] 0 0
Pátrai
Country [79] 0 0
Greece
State/province [79] 0 0
Thessaloniki
Country [80] 0 0
Hungary
State/province [80] 0 0
Budapest
Country [81] 0 0
Hungary
State/province [81] 0 0
Nyíregyháza
Country [82] 0 0
Hungary
State/province [82] 0 0
Szekszárd
Country [83] 0 0
Hungary
State/province [83] 0 0
Székesfehérvár
Country [84] 0 0
Italy
State/province [84] 0 0
Alessandria
Country [85] 0 0
Italy
State/province [85] 0 0
Ancona
Country [86] 0 0
Italy
State/province [86] 0 0
Bologna
Country [87] 0 0
Italy
State/province [87] 0 0
Brescia
Country [88] 0 0
Italy
State/province [88] 0 0
Catania
Country [89] 0 0
Italy
State/province [89] 0 0
Florence
Country [90] 0 0
Italy
State/province [90] 0 0
Forlì
Country [91] 0 0
Italy
State/province [91] 0 0
Milan
Country [92] 0 0
Italy
State/province [92] 0 0
Novara
Country [93] 0 0
Italy
State/province [93] 0 0
Orbassano
Country [94] 0 0
Italy
State/province [94] 0 0
Palermo
Country [95] 0 0
Italy
State/province [95] 0 0
Pavia
Country [96] 0 0
Italy
State/province [96] 0 0
Pesaro
Country [97] 0 0
Italy
State/province [97] 0 0
Reggio Emilia
Country [98] 0 0
Italy
State/province [98] 0 0
Rome
Country [99] 0 0
Italy
State/province [99] 0 0
Turin
Country [100] 0 0
Italy
State/province [100] 0 0
Varese
Country [101] 0 0
Poland
State/province [101] 0 0
Bialystok
Country [102] 0 0
Poland
State/province [102] 0 0
Gdansk
Country [103] 0 0
Poland
State/province [103] 0 0
Krakow
Country [104] 0 0
Poland
State/province [104] 0 0
Lodz
Country [105] 0 0
Poland
State/province [105] 0 0
Nowy Sacz
Country [106] 0 0
Poland
State/province [106] 0 0
Olsztyn
Country [107] 0 0
Poland
State/province [107] 0 0
Poznan
Country [108] 0 0
Poland
State/province [108] 0 0
Szczecin
Country [109] 0 0
Poland
State/province [109] 0 0
Slupsk
Country [110] 0 0
Poland
State/province [110] 0 0
Warsaw
Country [111] 0 0
Poland
State/province [111] 0 0
Walbrzych
Country [112] 0 0
Poland
State/province [112] 0 0
Wroclaw
Country [113] 0 0
Portugal
State/province [113] 0 0
Aveiro
Country [114] 0 0
Portugal
State/province [114] 0 0
Braga
Country [115] 0 0
Portugal
State/province [115] 0 0
Lisbon
Country [116] 0 0
Portugal
State/province [116] 0 0
Vila Nova de Gaia
Country [117] 0 0
Romania
State/province [117] 0 0
Brasov
Country [118] 0 0
Romania
State/province [118] 0 0
Bucharest
Country [119] 0 0
Romania
State/province [119] 0 0
Cluj-Napoca
Country [120] 0 0
Romania
State/province [120] 0 0
Oradea
Country [121] 0 0
Romania
State/province [121] 0 0
Târgu Mures
Country [122] 0 0
Serbia
State/province [122] 0 0
Belgrade
Country [123] 0 0
Serbia
State/province [123] 0 0
Kragujevac
Country [124] 0 0
Serbia
State/province [124] 0 0
Novi Sad
Country [125] 0 0
South Korea
State/province [125] 0 0
Busan
Country [126] 0 0
South Korea
State/province [126] 0 0
Daegu
Country [127] 0 0
South Korea
State/province [127] 0 0
Seoul
Country [128] 0 0
Spain
State/province [128] 0 0
Badalona
Country [129] 0 0
Spain
State/province [129] 0 0
Barcelona
Country [130] 0 0
Spain
State/province [130] 0 0
Cáceres
Country [131] 0 0
Spain
State/province [131] 0 0
Las Palmas de Gran Canaria
Country [132] 0 0
Spain
State/province [132] 0 0
Madrid
Country [133] 0 0
Spain
State/province [133] 0 0
Málaga
Country [134] 0 0
Spain
State/province [134] 0 0
Salamanca
Country [135] 0 0
Spain
State/province [135] 0 0
Valencia
Country [136] 0 0
Spain
State/province [136] 0 0
Zaragoza
Country [137] 0 0
United Kingdom
State/province [137] 0 0
Birmingham
Country [138] 0 0
United Kingdom
State/province [138] 0 0
Boston
Country [139] 0 0
United Kingdom
State/province [139] 0 0
Cambridge
Country [140] 0 0
United Kingdom
State/province [140] 0 0
Cardiff
Country [141] 0 0
United Kingdom
State/province [141] 0 0
Edinburgh
Country [142] 0 0
United Kingdom
State/province [142] 0 0
Gloucester
Country [143] 0 0
United Kingdom
State/province [143] 0 0
Harrogate
Country [144] 0 0
United Kingdom
State/province [144] 0 0
Leicester
Country [145] 0 0
United Kingdom
State/province [145] 0 0
Liverpool
Country [146] 0 0
United Kingdom
State/province [146] 0 0
London
Country [147] 0 0
United Kingdom
State/province [147] 0 0
Oxford
Country [148] 0 0
United Kingdom
State/province [148] 0 0
Windsor

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Kartos Therapeutics, Inc.
Address
Country
Secondary sponsor
Nil

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
John Mei
Address 0 0
Country 0 0
Phone 0 0
650-542-0136
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.